TRPC1 (Transient Receptor Potential Canonical 1) is a member of the TRP channel superfamily, which plays a critical role in calcium signaling and cellular homeostasis. TRPC1 forms non-selective cation channels, often functioning as homomers or heteromers with other TRPC subunits, and is implicated in regulating store-operated calcium entry (SOCE), mechanosensation, and cell proliferation. Its expression is widespread, including in the brain, cardiovascular system, and epithelial tissues, linking it to diverse physiological and pathological processes such as neuronal development, cardiac hypertrophy, and cancer progression.
TRPC1-specific antibodies are essential tools for studying the protein's expression, localization, and function. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to validate TRPC1 in tissue samples, cultured cells, or disease models. Research utilizing these antibodies has revealed TRPC1's involvement in neurodegenerative diseases (e.g., Alzheimer's), cardiovascular disorders, and tumorigenesis, where dysregulated calcium signaling contributes to pathology. Some studies also explore TRPC1 as a potential therapeutic target or biomarker. However, antibody specificity remains a challenge due to homology among TRP subunits, necessitating careful validation via knockout controls or siRNA-based approaches. Commercial TRPC1 antibodies are typically raised against conserved epitopes in human, mouse, or rat sequences, enabling cross-species applications in translational research.